Everolimus in patients with metastatic renla cell carcinoma previously treated with sunitinib or pazopanib

Update Il y a 4 ans
Reference: EUCTR2011-003416-23

Woman and Man

  • | Country :
  • -
  • | organs :
  • -
  • | Specialty :
  • -

Extract

The primary objective of the study is to assess the efficacy of everolimus in patients with metastatic renal cell cancer whose disease progressed on or after prior first-line treatment with sunitinib or pazopanib. Efficacy will be measured by the rate of patients who are free of disease progression after 6 months of treatment with everolimus.


Inclusion criteria

  • Metastatic Renal Cell Carcinoma

Links